Bimekizumab use for 4 years among patients with plaque psoriasis is associated with sustained efficacy outcomes and no new safety signals.

For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by high-sensitivity C-reactive protein, despite ...

She was diagnosed with alopecia areata, an autoimmune condition that disrupts regular hair growth, at just 18 months old and ...

Dr. Orbai has observed that the incidence of thyroid disease is higher in women who also have another ... who have the most common type of psoriasis, plaque psoriasis, there is not a clear ...

Improved clinical efficacy measures and biomarkers in patients with mild-to-moderated active plaque psoriasis. Weisel et al 48 Quarterly subcutaneous administration of canakinumab decreased hsCRP ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.

Certain biologic therapies, such as ustekinumab, significantly effect hematological and lipid parameters in patients with psoriasis.

The programme comprises two Phase III trials, ONWARD1 and ONWARD2, and an optional long-term extension trial, ONWARD3.